Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

• Eligible patients of either sex, 15 years of age or older

• Patients who are admitted to the department of hematology and oncology

• Provide written informed consent

Exclusion Criteria:

• Patients who have hypersensitivity to β-lactam antibiotics

• Female who are pregnant or breast-feeding

• Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days